109 related articles for article (PubMed ID: 19520574)
1. Synthesis, structure-activity relationships, and biological profiles of a dihydrobenzoxathiin class of histamine H(3) receptor inverse agonists.
Sasaki T; Takahashi T; Nagase T; Mizutani T; Ito S; Mitobe Y; Miyamoto Y; Kanesaka M; Yoshimoto R; Tanaka T; Takenaga N; Tokita S; Sato N
Bioorg Med Chem Lett; 2009 Aug; 19(15):4232-6. PubMed ID: 19520574
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and evaluation of 4-alkoxy-[1'-cyclobutyl-spiro(3,4-dihydrobenzopyran-2,4'-piperidine)] analogues as histamine-3 receptor antagonists.
Becknell NC; Dandu RR; Lyons JA; Aimone LD; Raddatz R; Hudkins RL
Bioorg Med Chem Lett; 2012 Jan; 22(1):186-9. PubMed ID: 22153342
[TBL] [Abstract][Full Text] [Related]
3. Identification of biaryl sulfone derivatives as antagonists of the histamine H₃ receptor: discovery of (R)-1-(2-(4'-(3-methoxypropylsulfonyl)biphenyl-4-yl)ethyl)-2-methylpyrrolidine (APD916).
Semple G; Santora VJ; Smith JM; Covel JA; Hayashi R; Gallardo C; Ibarra JB; Schultz JA; Park DM; Estrada SA; Hofilena BJ; Smith BM; Ren A; Suarez M; Frazer J; Edwards JE; Hart R; Hauser EK; Lorea J; Grottick AJ
Bioorg Med Chem Lett; 2012 Jan; 22(1):71-5. PubMed ID: 22172695
[TBL] [Abstract][Full Text] [Related]
4. Development of a selective and potent radioactive ligand for histamine H(3) receptors: A compound potentially useful for receptor occupancy studies.
Mitobe Y; Ito S; Mizutani T; Nagase T; Sato N; Tokita S
Bioorg Med Chem Lett; 2009 Aug; 19(15):4075-8. PubMed ID: 19553110
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, structure-activity relationships, and biological profiles of a quinazolinone class of histamine H3 receptor inverse agonists.
Nagase T; Mizutani T; Ishikawa S; Sekino E; Sasaki T; Fujimura T; Ito S; Mitobe Y; Miyamoto Y; Yoshimoto R; Tanaka T; Ishihara A; Takenaga N; Tokita S; Fukami T; Sato N
J Med Chem; 2008 Aug; 51(15):4780-9. PubMed ID: 18598020
[TBL] [Abstract][Full Text] [Related]
6. Development of novel 2-[4-(aminoalkoxy)phenyl]-4(3H)-quinazolinone derivatives as potent and selective histamine H3 receptor inverse agonists.
Mizutani T; Nagase T; Ito S; Miyamoto Y; Tanaka T; Takenaga N; Tokita S; Sato N
Bioorg Med Chem Lett; 2008 Dec; 18(23):6041-5. PubMed ID: 18952421
[TBL] [Abstract][Full Text] [Related]
7. 4,5-dihydropyridazin-3-one derivatives as histamine H₃ receptor inverse agonists.
Hudkins RL; Aimone LD; Dandu RR; Dunn D; Gruner JA; Huang Z; Josef KA; Lyons JA; Mathiasen JR; Tao M; Zulli AL; Raddatz R
Bioorg Med Chem Lett; 2012 Jan; 22(1):194-8. PubMed ID: 22142542
[TBL] [Abstract][Full Text] [Related]
8. 2-(Pyrrolidin-1-yl)ethyl-3,4-dihydroisoquinolin-1(2H)-one derivatives as potent and selective histamine-3 receptor antagonists.
Zhou D; Gross JL; Adedoyin AB; Aschmies SB; Brennan J; Bowlby M; Di L; Kubek K; Platt BJ; Wang Z; Zhang G; Brandon N; Comery TA; Robichaud AJ
J Med Chem; 2012 Mar; 55(5):2452-68. PubMed ID: 22313242
[TBL] [Abstract][Full Text] [Related]
9. 2,4-Diaminopyridine delta-opioid receptor agonists and their associated hERG pharmacology.
Owen DR; Rodriguez-Lens M; Corless MD; Gaulier SM; Horne VA; Kinloch RA; Maw GN; Pearce DW; Rees H; Ringer TJ; Ryckmans T; Stammen BL
Bioorg Med Chem Lett; 2009 Mar; 19(6):1702-6. PubMed ID: 19231185
[TBL] [Abstract][Full Text] [Related]
10. A new class of histamine H3 receptor antagonists derived from ligand based design.
Roche O; Rodríguez Sarmiento RM
Bioorg Med Chem Lett; 2007 Jul; 17(13):3670-5. PubMed ID: 17498953
[TBL] [Abstract][Full Text] [Related]
11. Selective naphthalene H(3) receptor inverse agonists with reduced potential to induce phospholipidosis and their quinoline analogs.
Rodríguez Sarmiento RM; Nettekoven MH; Taylor S; Plancher JM; Richter H; Roche O
Bioorg Med Chem Lett; 2009 Aug; 19(15):4495-500. PubMed ID: 19524437
[TBL] [Abstract][Full Text] [Related]
12. Design and synthesis of a novel series of histamine H3 receptor antagonists through a scaffold hopping strategy.
Gao Z; Hurst WJ; Hall D; Hartung R; Reynolds W; Kang J; Nagorny R; Hendrix JA; George PG
Bioorg Med Chem; 2015 Feb; 23(3):429-38. PubMed ID: 25577710
[TBL] [Abstract][Full Text] [Related]
13. Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.
Coon T; Moree WJ; Li B; Yu J; Zamani-Kord S; Malany S; Santos MA; Hernandez LM; Petroski RE; Sun A; Wen J; Sullivan S; Haelewyn J; Hedrick M; Hoare SJ; Bradbury MJ; Crowe PD; Beaton G
Bioorg Med Chem Lett; 2009 Aug; 19(15):4380-4. PubMed ID: 19553115
[TBL] [Abstract][Full Text] [Related]
14. Novel H3 receptor antagonists with improved pharmacokinetic profiles.
Santora VJ; Covel JA; Hayashi R; Hofilena BJ; Ibarra JB; Pulley MD; Weinhouse MI; Semple G; Ren A; Pereira G; Edwards JE; Suarez M; Frazer J; Thomsen W; Hauser E; Lorea J; Grottick AJ
Bioorg Med Chem Lett; 2008 Jul; 18(14):4133-6. PubMed ID: 18554904
[TBL] [Abstract][Full Text] [Related]
15. Discovery and characterization of 6-{4-[3-(R)-2-methylpyrrolidin-1-yl)propoxy]phenyl}-2H-pyridazin-3-one (CEP-26401, irdabisant): a potent, selective histamine H3 receptor inverse agonist.
Hudkins RL; Raddatz R; Tao M; Mathiasen JR; Aimone LD; Becknell NC; Prouty CP; Knutsen LJ; Yazdanian M; Moachon G; Ator MA; Mallamo JP; Marino MJ; Bacon ER; Williams M
J Med Chem; 2011 Jul; 54(13):4781-92. PubMed ID: 21634396
[TBL] [Abstract][Full Text] [Related]
16. The design and synthesis of potent and cell-active allosteric dual Akt 1 and 2 inhibitors devoid of hERG activity.
Siu T; Li Y; Nagasawa J; Liang J; Tehrani L; Chua P; Jones RE; Defeo-Jones D; Barnett SF; Robinson RG
Bioorg Med Chem Lett; 2008 Jul; 18(14):4191-4. PubMed ID: 18550373
[TBL] [Abstract][Full Text] [Related]
17. Potent and selective small-molecule human urotensin-II antagonists with improved pharmacokinetic profiles.
McAtee JJ; Dodson JW; Dowdell SE; Erhard K; Girard GR; Goodman KB; Hilfiker MA; Jin J; Sehon CA; Sha D; Shi D; Wang F; Wang GZ; Wang N; Wang Y; Viet AQ; Yuan CC; Zhang D; Aiyar NV; Behm DJ; Carballo LH; Evans CA; Fries HE; Nagilla R; Roethke TJ; Xu X; Douglas SA; Neeb MJ
Bioorg Med Chem Lett; 2008 Jul; 18(13):3716-9. PubMed ID: 18524591
[TBL] [Abstract][Full Text] [Related]
18. Cyclopropane-based conformational restriction of histamine. (1S,2S)-2-(2-aminoethyl)-1-(1H-imidazol-4-yl)cyclopropane, a highly selective agonist for the histamine H3 receptor, having a cis-cyclopropane structure.
Kazuta Y; Hirano K; Natsume K; Yamada S; Kimura R; Matsumoto S; Furuichi K; Matsuda A; Shuto S
J Med Chem; 2003 May; 46(10):1980-8. PubMed ID: 12723960
[TBL] [Abstract][Full Text] [Related]
19. Ergoline-derived inverse agonists of the human h3 receptor for the treatment of narcolepsy.
Auberson YP; Troxler T; Zhang X; Yang CR; Fendt M; Feuerbach D; Liu YC; Lagu B; Lerchner A; Perrone M; Lei L; Zhang C; Wang C; Wang TL; Bock MG
ChemMedChem; 2014 Aug; 9(8):1683-96. PubMed ID: 24850792
[TBL] [Abstract][Full Text] [Related]
20. 4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.
Procopiou PA; Ancliff RA; Bamford MJ; Browning C; Connor H; Davies S; Fogden YC; Hodgson ST; Holmes DS; Looker BE; Morriss KM; Parr CA; Pickup EA; Sehmi SS; White GV; Watts CJ; Wilson DM; Woodrow MD
J Med Chem; 2007 Dec; 50(26):6706-17. PubMed ID: 18052318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
